Skip Navigation LinksIntegrated Review Groups > Oncology 2 - Translational Clinical IRG [OTC] > Radiation Therapeutics and Biology Study Section [RTB]

Radiation Therapeutics and Biology Study Section [RTB]

The Radiation Therapeutics and Biology (RTB) Study Section reviews applications on therapeutic interactions of ionizing radiation, radionuclides, electromagnetic radiation, and heat at the molecular, cellular, organ, and patient levels. This ranges from basic studies of DNA damage responses and DNA repair to preclinical applications in which dose, dose rate, type of radiation, and quality of radiation are variables. RTB focuses on both clinical work and animal model.

Rosters

Topics

  • Basic molecular, cellular-radiation, and thermal interactions at therapeutic doses: radiation chemistry, DNA damage and repair, cell cycle regulation, hypoxia, signal transduction, apoptosis, heat shock proteins, growth factors, cytokines, oxidative stress, reactive oxygen species, tumor suppressor genes, cytogenetics, genomic instability, as well as UV and radiation carcinogenesis and investigations of mechanisms of DNA damage and repair.
  • Mechanisms and applications of modifiers of radiation response (including radiation sensitizers, radioprotectors, fractionation, hypoxia, and other modulators) and combination of radiation with novel agents (including those targeting growth factors, signaling pathways, DNA repair, and tumor angiogenesis).
  • Physics of treatment planning, treatment delivery, and dosimetry of brachytherapy, intravascular brachytherapy, thermal therapy, targeted radionuclide therapy, photodynamic therapy (PDT), heavy ion or neutron capture therapy, and technology and outcome analysis methodologies related to radiation treatment and planning.
  • Therapies including: intensity modulation radiation therapy (IMRT), brachytherapy, chemoradiotherapy, conformal therapy, tomotherapy, PDT (including interstitial PDT), photoimmunotherapy, hyperthermia, radiofrequency ablation, cryoablation, intravascular radiotherapy, radiation-induced gene therapy, radionuclide therapy, feasibility studies to establish proof-of-principle of novel radiation therapeutics or combinations of radiation with systemic agents, as well as image-guided therapy and other imaging and image analysis as it relates to targeting of radiation and assessment of response.
  • Pre-clinical studies to model radiation therapeutics, tumor biology, and radiation response modulation including: pharmacokinetics, response assessment, efficacy, and internal dosimetry of targeted radio labeled agents (including antibodies, peptides, oligonucleotides, liposomes, and nanoparticles).

Shared Interests and Overlaps

​​

There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT1) / Mechanisms of Cancer Therapeutics-2 (MCT2). Applications involving DNA repair and gene regulation aspects with focus on the effect of anti-neoplastic agents on tumor cell anabolic processes may be assigned to MCT1/MCT2. Applications studying the radiation carcinogenesis and investigations of mechanisms of DNA damage and repair may be assigned to RTB.

There are shared interests with Developmental Therapeutics (DT). Applications with focus on the evaluation of novel anticancer therapeutic and drug-delivery strategies may be assigned to DT. Applications with focus on the studies of targeted radio-labeled agents and their pharmacokinetics, response assessment, and efficacy may be assigned to RTB.

There are shared interests with Clinical Oncology (CONC). Applications with focus on the clinical therapy trials may be assigned to CONC. Application with emphasis on the clinical work and animal model pertaining to radiation therapy, radiopharmaceuticals, combined modality therapy, and radioimmunotherapy may be assigned to RTB.

There are shared interests with Cancer Immunopathology and Immunotherapy (CII). Applications with focus on the immunologic therapies of cancer and evaluation of immunotherapeutic strategies may be assigned to CII. Applications with emphasis on radioimmunotherapy and photoimmunotherapy, along with the therapeutic and diagnostic uses of antibodies pertaining to such therapies, may be assigned to RTB.

There are shared interests with Nanotechnology (NANO). Applications with focus on the designs and properties of nanostructures may be assigned to NANO. Applications that use nanoparticles and nanomaterials for radiation therapeutic studies may be assigned to RTB.

There are shared interests with Cancer Etiology (CE). Applications with focus on the role of DNA damage associated with early events in carcinogenesis may be assigned to CE. Applications with focus on studies of DNA damage responses and DNA repair, UV and radiation carcinogenesis, and the associated investigations of mechanisms of DNA damage and repair may be assigned to RTB.

There are shared interests with Molecular Genetics A (MGA) and Molecular Genetics B (MGB). Applications with focus on DNA metabolism and molecular mechanisms of genome replication may be assigned to MGA and MGB. Applications with emphasis on investigations of mechanisms of DNA damage/repair and combination of radiation with novel agents, such as targeting growth factors, signaling pathways, DNA repair, and tumor angiogenesis, may be assigned to RTB.

There are shared interests with Medical Imaging (MEDI). Applications with focus on the evaluation of imaging methodologies and Image-guided interventions may be assigned to MEDI. Applications with focus on the imaging and image analysis as it relates to targeting of radiation and assessment of therapeutic response may be assigned to RTB.

There are shared interests with Biomedical Imaging Technology A (BMIT-A) and Biomedical Imaging Technology (BMIT-B). Applications with emphasis on the development of image-based methods and strategies may be assigned to BMIT-A and BMIT-B. Applications with focus on image-guided therapy and other imaging and image analysis associated with targeting of radiation and response assessment may be assigned to RTB.

There are shared interests with Clinical Molecular Imaging and Probe Development (CMIP). Applications with focus on the development of targeted molecular imaging agents may be assigned to CMIP. Applications with emphasis on radionuclides, radiochemistry, and feasibility studies to establish proof-of-principle of novel radiation therapeutics may be assigned to RTB.